For example, an association between a genetic polymorphism of interleukin-6 receptor (IL-6R) and risk of coronary heart disease has led to RCTs of tocilizumab, an IL-6R inhibitor (also an effective biological disease-modifying anti-rheumatic drug DMARD), in myocardial infarction [28]. Here, IL6R is linked to coronary artery disorder.